Phase 4 N=129 Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema
Acute Cardiogenic Pulmonary Edema
Primary: Number of Patients Who Were Intubated — 5; 4; 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=114 Non-invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema
Cardiogenic Pulmonary Oedema
Primary: Need for an Endotracheal Intubation Within Seven Days After Onset of Cardiopulmonary Edema at the Intensive Care Unit — 5; 5 Participants — p=1.000
Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
N/A N=746 Pulmonary Embolism as a Cause of COPD Exacerbations
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Phase 3 N=52 A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -2.05; -1.31; -2.9 Kg
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
Phase 2 N=122 A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Heart Failure, Congestive · Edema
Primary: Body Weight — -0.53; -1.62; -1.35; -1.85 Kg — p=0.0074
Phase 2 N=157 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Cardiac Edema (CHF)
Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg
N/A N=65,406 Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Pulmonary Disease, Chronic Obstructive
Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events
N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
N/A N=23 Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
Obstructive Sleep Apnea · Chronic Obstructive Pulmonary Disease · Overlap Syndrome
Primary: Right Ventricular Remodeling Index — 0.3747; 0.2817 ratio
N/A N=15 Simple Non-invasive Breathing Device to Improve Pulmonary Flow Pusatility in Single Ventricle Post Fontan
Single-ventricle
Primary: Change in Pulmonary Pulsatility Index — 51.6; 57.6 Ratio — p=0.1
Phase 1 N=36 A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Heart Failure, Congestive
Primary: Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline — 0.4946; 0.3346; 0.5078; 0.3253 Liter — p=0.0029
Phase 4 N=74 Oxygen Versus PAP for Sleep Apnea in Heart Failure
Heart Failure · Sleep Apnea Syndromes
Primary: Left Ventricular Ejection Fraction — 1.63; 1.69; 4.42 percent of LV diastolic volume
Phase 2 N=130 B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
N/A N=320 Intensive Alveolar Recruitment Protocol After Cardiac Surgery
Ventilator Induced Lung Injury · Cardiac Disease · Acute Lung Injury
Primary: Severity of Pulmonary Complications in the Post-operative Period — 15; 26 percentage of participants — p=0.016
N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
Phase 4 N=42 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
Heart Failure
Primary: Change in Peak VO2 (Oxygen Consumption ) — 1.21; 0.48 ml/kg/min
Phase 4 N=30 Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Pulmonary Hypertension
Primary: Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a…
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
N/A N=13 Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients
Sleep Apnea, Obstructive · Heart Failure
Primary: All-cause Hospital Readmission Within 30 Days of Hospital Discharge. — 3 readmissions
N/A N=50 B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading
Fluid Over-load
Primary: Length of Stay — 4; 6 days
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
N/A N=406 National Cardiogenic Shock Initiative
Cardiogenic Shock · Acute Myocardial Infarction · STEMI - ST Elevation Myocardial Infarction
Primary: Number of Participants Who Survived at Discharge — 287 Participants
N/A N=180 A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9